Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

Newly Allowed Patent Protects Cell-Free MyeloCelz™ Exosome Technology Designed to Suppress Autoimmune Destruction of Insulin-Producing Cells, Reinforcing Creative Medical's Multi-Program Diabetes Strategy

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled “ Suppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells ” (U.S. Application No. 17/931,868).

Once formally issued, the patent will extend Creative Medical’s intellectual property protection around its proprietary MyeloCelz™ platform, a cell-free exosome technology derived from stem-cell-programmed myeloid cells that is designed to induce antigen-specific immune tolerance and suppress the autoimmune destruction of insulin-producing pancreatic beta cells that underlies Type 1 diabetes (T1D). The allowed claims cover the use of these exosomes alone, or in combination with other tolerance-promoting agents such as antibodies, cellular therapies and small molecules, to selectively shut down the immune cells responsible for attacking the pancreas while preserving the immune system’s ability to fight infection and disease.

Strengthening a Multi-Layered Patent Estate Around Creative Medical's Diabetes Franchise

This Notice of Allowance is the latest in a series of USPTO actions strengthening Creative Medical’s intellectual property position across its immunology and endocrinology pipeline. It follows the Company’s prior Notices of Allowance covering “Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity” and “Treatment of Heart Failure and/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells,” both of which were subsequently issued as U.S. Patent Nos. 12,931,925 and 12,385,011, respectively, providing protection into 2042 and 2043. The newly allowed exosome patent directly complements the Company’s broader diabetes portfolio, which spans multiple stages of disease and mechanisms of action: CELZ-201 (olastrocel/AlloStem ® ) , currently being evaluated in the FDA-cleared CREATE-1 trial for newly diagnosed T1D; CELZ-101 (etaroleucel/ImmCelz ® ) , which holds FDA Orphan Drug Designation for use alongside pancreatic islet transplantation in brittle T1D; and CELZ-001 , the Company’s program for late-stage Type 2 diabetes.

Creative Medical’s overall intellectual property estate now comprises approximately 60 issued patents and pending applications, with seven issued U.S. patents and 39 pending U.S. applications on file with the USPTO. “Each new Notice of Allowance adds another layer of protection around the core biology that differentiates our platform,” said Timothy Warbington, President and CEO of Creative Medical Technology Holdings . “This exosome-based approach gives us a cell-free way to pursue the same antigen-specific tolerance mechanism we are already advancing clinically with CELZ-101 and CELZ-201. Building overlapping IP protection across both our cellular and cell-free diabetes programs is a deliberate strategy to maximize the long-term value of our platform for patients and shareholders alike.”

A Large and Growing Market Opportunity in Type 1 Diabetes Type 1 diabetes remains a lifelong autoimmune condition with no approved cur...